Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 56 people in total — 28 received the medicine abatacept and 28 received a placebo (a dummy treatment with no active ingredient). The participants all had a condition called undifferentiated inflammatory arthritis, meaning joint inflammation that had not yet been formally diagnosed as a specific disease. The trial was trying to find out how many people went on to develop rheumatoid arthritis (a longer-term joint condition) over the course of the study, which included a six-month treatment phase followed by an 18-month observation period where no treatment was given. The reported data shows that for the main outcome — the number of people who either received a formal diagnosis of rheumatoid arthritis or left the study early because the treatment wasn't working for them — 12 out of 28 people in the abatacept group and 16 out of 28 in the placebo group met this measure. For a secondary version of this same measure using a slightly different set of diagnostic criteria, the reported numbers were 17 out of 28 in the abatacept group and 21 out of 28 in the placebo group. The reported data also shows scores measuring joint damage and inflammation (assessed by X-ray and MRI scans) at six months, 12 months, and 24 months, with various numerical changes from starting scores recorded for both groups across those time points. No participants in either group were reported to have developed a different rheumatic disease during the study. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 19933744) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Rheumatoid Arthritis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with a type of early, not fully defined joint inflammation called "undifferentiated arthritis."
- You have visible joint swelling (synovitis) in two or more joints.
- You meet at least one, but no more than three, of the standard medical checklist items used to diagnose rheumatoid arthritis (based on 1987 guidelines).
- You have never taken disease-modifying or biologic medicines for your joint condition.
- Your joint condition has been present for 18 months or less.
- A blood test has shown that you are positive for certain antibodies (anti-CCP antibodies) linked to rheumatoid arthritis.
Who may not be able to join:
- Women who could become pregnant but are unwilling or unable to use a reliable method of contraception during the trial.
- People who have serious inflammation of the blood vessels affecting a major organ (confirm with trial site).
- People who have serious or frequently recurring bacterial infections.
- People who have had a cancer diagnosis in the last five years, with the exception of certain types of skin cancer.
- People who have recently had a shingles (herpes zoster) infection that cleared up less than 2 months before joining the trial.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Bristol-Myers Squibb, Bristol-Myers Squibb
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
4 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Number of Participants With a Diagnosis of Rheumatoid Arthritis (RA) by American Rheumatism Association (ARA) Criteria and/or Discontinued Due to Lack of Efficacy
Can't join this trial?
Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.